# HIV Infections FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hiv-infections

> 6 upcoming FDA catalysts in HIV Infections: VH4524184 (GSK) on Oct 2027 to Jan 2028 (topline data readout); VH4524184 (GSK) on October 2027 (primary completion); cab la (GSK) on Mar to Jun 2029 (topline data readout); Yeztugo® (lenacapavir, GILD) on March 2029 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 16, 2025 | [Dtg/3tc primary completion](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV Infections | completed | "NCT05917509 (A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05917509)) |
| May 27, 2026 | [Vocabria (cabotegravir sodium) primary completion](https://sec-api.dev/pdufa/cabotegravir) | GSK | HIV Infections | completed | "NCT05996471 (A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05996471)) |
| August 19, 2026 | [Cab la + rpv la primary completion](https://sec-api.dev/pdufa/cab-la-rpv-la) | GSK | HIV Infections | completed | "NCT06694805 (A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694805)) |
| Aug to Nov 2026 | [Cab la + rpv la topline data readout](https://sec-api.dev/pdufa/cab-la-rpv-la) | GSK | HIV Infections | scheduled | "NCT06694805 (A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694805)) |
| September 9, 2026 | [Cab la primary completion](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | completed | "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741397)) |
| Sep to Dec 2026 | [Cab la topline data readout](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741397)) |
| Oct 2027 to Jan 2028 | [VH4524184 topline data readout](https://sec-api.dev/pdufa/vh4524184) | GSK | HIV Infections | scheduled | "NCT07202546 (A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202546)) |
| October 2027 | [VH4524184 primary completion](https://sec-api.dev/pdufa/vh4524184) | GSK | HIV Infections | scheduled | "NCT07202546 (A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202546)) |
| Mar to Jun 2029 | [Cab la topline data readout](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06134362)) |
| March 2029 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Infections | scheduled | "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682961)) |
| Mar to Jun 2029 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Infections | scheduled | "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682961)) |
| March 2029 | [Cab la primary completion](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06134362)) |

## Drugs

- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)
- [Vocabria (cabotegravir sodium)](https://sec-api.dev/pdufa/cabotegravir) (GSK)
- [Cab la + rpv la](https://sec-api.dev/pdufa/cab-la-rpv-la) (GSK)
- [Cab la](https://sec-api.dev/pdufa/cab-la) (GSK)
- [VH4524184](https://sec-api.dev/pdufa/vh4524184) (GSK)
- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hiv-infections.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HIV Infections FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hiv-infections

```bibtex
@misc{secapidev_indications_hiv_infections_20261116,
  title        = {HIV Infections FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hiv-infections}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hiv_infections_20261116","title":"HIV Infections FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hiv-infections","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
